Anavo Therapeutics BV

Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications. Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures

Drug discovery,phospatase biology,and oncology

Anavo therapeutics bv operates in the Biotechnology research industry.

Anavo therapeutics bv's revenue is 1m - 10m

Anavo therapeutics bv has 11 - 50 employees.